Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Tract Infections | 31 | 2024 | 804 | 7.050 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 20 | 2021 | 705 | 3.880 |
Why?
|
Staphylococcal Infections | 20 | 2023 | 1396 | 3.400 |
Why?
|
Surgical Wound Infection | 14 | 2024 | 1547 | 2.770 |
Why?
|
Anti-Bacterial Agents | 40 | 2024 | 7475 | 2.760 |
Why?
|
Antibiotic Prophylaxis | 11 | 2019 | 641 | 2.700 |
Why?
|
Cystitis | 10 | 2023 | 96 | 2.400 |
Why?
|
Carrier State | 8 | 2021 | 530 | 2.090 |
Why?
|
Bacteriuria | 5 | 2019 | 102 | 1.900 |
Why?
|
Cross Infection | 17 | 2024 | 1427 | 1.800 |
Why?
|
Anti-Infective Agents | 8 | 2020 | 987 | 1.710 |
Why?
|
Vancomycin | 8 | 2022 | 504 | 1.660 |
Why?
|
Drug Resistance, Multiple, Bacterial | 10 | 2018 | 592 | 1.520 |
Why?
|
Clostridium Infections | 7 | 2022 | 563 | 1.500 |
Why?
|
Infection Control | 8 | 2021 | 984 | 1.180 |
Why?
|
Anti-Infective Agents, Urinary | 4 | 2011 | 28 | 1.180 |
Why?
|
Pyuria | 2 | 2020 | 30 | 1.090 |
Why?
|
Mass Screening | 8 | 2021 | 5454 | 0.960 |
Why?
|
Escherichia coli Infections | 6 | 2016 | 518 | 0.920 |
Why?
|
Diagnostic Tests, Routine | 3 | 2020 | 789 | 0.910 |
Why?
|
Hospitals, Veterans | 10 | 2021 | 395 | 0.910 |
Why?
|
Pyelonephritis | 5 | 2011 | 77 | 0.900 |
Why?
|
Nitrofurantoin | 3 | 2023 | 18 | 0.870 |
Why?
|
Patients' Rooms | 2 | 2014 | 63 | 0.860 |
Why?
|
Acute Kidney Injury | 4 | 2019 | 1946 | 0.820 |
Why?
|
Catheter-Related Infections | 3 | 2016 | 279 | 0.810 |
Why?
|
Nasal Cavity | 3 | 2014 | 310 | 0.770 |
Why?
|
Residential Facilities | 1 | 2021 | 41 | 0.760 |
Why?
|
beta-Lactams | 2 | 2017 | 158 | 0.760 |
Why?
|
Drug Resistance, Bacterial | 8 | 2023 | 1065 | 0.750 |
Why?
|
Asymptomatic Infections | 3 | 2019 | 136 | 0.690 |
Why?
|
Nasal Mucosa | 3 | 2012 | 416 | 0.690 |
Why?
|
Health Personnel | 6 | 2023 | 3384 | 0.690 |
Why?
|
Common Cold | 1 | 2020 | 63 | 0.680 |
Why?
|
Soft Tissue Infections | 3 | 2020 | 166 | 0.650 |
Why?
|
Urinalysis | 4 | 2024 | 369 | 0.650 |
Why?
|
Antibodies, Viral | 2 | 2021 | 3212 | 0.640 |
Why?
|
Natural Language Processing | 5 | 2016 | 1203 | 0.630 |
Why?
|
Immunoglobulin G | 2 | 2021 | 4559 | 0.620 |
Why?
|
Cross Reactions | 1 | 2020 | 826 | 0.600 |
Why?
|
Lactobacillus | 2 | 2012 | 212 | 0.600 |
Why?
|
Nasopharynx | 1 | 2020 | 419 | 0.550 |
Why?
|
Mupirocin | 3 | 2013 | 55 | 0.540 |
Why?
|
Orthopedic Procedures | 2 | 2024 | 1279 | 0.540 |
Why?
|
Ultrasound, High-Intensity Focused, Transrectal | 1 | 2015 | 6 | 0.520 |
Why?
|
Sulfanilamides | 1 | 2015 | 14 | 0.520 |
Why?
|
Population Surveillance | 3 | 2020 | 2594 | 0.510 |
Why?
|
Veterans | 8 | 2023 | 2667 | 0.510 |
Why?
|
Fosfomycin | 1 | 2015 | 26 | 0.510 |
Why?
|
Bacterial Infections | 3 | 2017 | 1390 | 0.490 |
Why?
|
Electronic Health Records | 9 | 2020 | 4880 | 0.480 |
Why?
|
Nose | 3 | 2013 | 522 | 0.460 |
Why?
|
Housekeeping, Hospital | 1 | 2014 | 17 | 0.450 |
Why?
|
Environmental Microbiology | 1 | 2014 | 47 | 0.450 |
Why?
|
Drug Resistance, Microbial | 2 | 2015 | 832 | 0.440 |
Why?
|
Computer Systems | 1 | 2015 | 467 | 0.440 |
Why?
|
Education, Professional | 1 | 2014 | 53 | 0.440 |
Why?
|
Boston | 9 | 2021 | 9346 | 0.430 |
Why?
|
beta-Lactamases | 1 | 2015 | 308 | 0.430 |
Why?
|
Urinary Tract | 2 | 2015 | 305 | 0.430 |
Why?
|
Disease Outbreaks | 3 | 2022 | 1761 | 0.430 |
Why?
|
Reminder Systems | 2 | 2019 | 389 | 0.430 |
Why?
|
Ciprofloxacin | 4 | 2023 | 314 | 0.420 |
Why?
|
Occupational Diseases | 1 | 2021 | 1456 | 0.420 |
Why?
|
Staphylococcus aureus | 3 | 2023 | 1429 | 0.410 |
Why?
|
Humans | 108 | 2024 | 766766 | 0.410 |
Why?
|
Pacemaker, Artificial | 4 | 2020 | 828 | 0.410 |
Why?
|
Hysterectomy | 1 | 2018 | 863 | 0.400 |
Why?
|
Vaccinium macrocarpon | 1 | 2012 | 11 | 0.400 |
Why?
|
United States Department of Veterans Affairs | 6 | 2021 | 937 | 0.400 |
Why?
|
Luminescent Measurements | 1 | 2014 | 342 | 0.400 |
Why?
|
Molecular Typing | 1 | 2012 | 115 | 0.390 |
Why?
|
Skin Diseases, Bacterial | 1 | 2012 | 65 | 0.390 |
Why?
|
Algorithms | 5 | 2021 | 14072 | 0.390 |
Why?
|
Escherichia coli | 7 | 2023 | 4211 | 0.380 |
Why?
|
Disinfection | 1 | 2014 | 207 | 0.380 |
Why?
|
Bacteremia | 2 | 2016 | 987 | 0.380 |
Why?
|
Urinary Catheterization | 1 | 2012 | 195 | 0.380 |
Why?
|
Surgical Mesh | 4 | 2021 | 315 | 0.380 |
Why?
|
Veterans Health | 2 | 2019 | 216 | 0.370 |
Why?
|
Microbial Sensitivity Tests | 6 | 2023 | 1972 | 0.350 |
Why?
|
Staphylococcal Skin Infections | 1 | 2011 | 78 | 0.350 |
Why?
|
Prosthesis-Related Infections | 4 | 2020 | 497 | 0.340 |
Why?
|
Chlorhexidine | 2 | 2011 | 159 | 0.330 |
Why?
|
Azepines | 1 | 2011 | 329 | 0.320 |
Why?
|
Vaccination | 1 | 2021 | 3434 | 0.320 |
Why?
|
Health Services Research | 3 | 2017 | 1811 | 0.320 |
Why?
|
Lactones | 1 | 2011 | 316 | 0.310 |
Why?
|
Inappropriate Prescribing | 1 | 2011 | 212 | 0.310 |
Why?
|
Secondary Prevention | 3 | 2024 | 1469 | 0.300 |
Why?
|
Polymerase Chain Reaction | 5 | 2021 | 6066 | 0.290 |
Why?
|
Asymptomatic Diseases | 1 | 2011 | 588 | 0.290 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2006 | 0.290 |
Why?
|
Female | 51 | 2024 | 396520 | 0.290 |
Why?
|
Adenosine Triphosphate | 1 | 2014 | 2001 | 0.290 |
Why?
|
Hernia, Ventral | 2 | 2021 | 220 | 0.280 |
Why?
|
Surgical Procedures, Operative | 1 | 2019 | 1931 | 0.280 |
Why?
|
Disease Transmission, Infectious | 2 | 2014 | 560 | 0.270 |
Why?
|
Methicillin Resistance | 1 | 2007 | 198 | 0.270 |
Why?
|
Middle Aged | 37 | 2024 | 223257 | 0.270 |
Why?
|
Beverages | 1 | 2012 | 819 | 0.260 |
Why?
|
Risk Factors | 19 | 2024 | 74881 | 0.260 |
Why?
|
Myeloid Cells | 1 | 2011 | 838 | 0.260 |
Why?
|
Community-Acquired Infections | 2 | 2007 | 470 | 0.260 |
Why?
|
Disease Management | 4 | 2019 | 2533 | 0.250 |
Why?
|
Recurrence | 8 | 2024 | 8507 | 0.250 |
Why?
|
Sepsis | 2 | 2020 | 2604 | 0.250 |
Why?
|
Bacterial Adhesion | 1 | 2006 | 306 | 0.240 |
Why?
|
Aged | 30 | 2021 | 171343 | 0.240 |
Why?
|
United States | 21 | 2024 | 72951 | 0.240 |
Why?
|
Male | 39 | 2024 | 364142 | 0.240 |
Why?
|
Incidence | 9 | 2021 | 21525 | 0.230 |
Why?
|
Rectum | 2 | 2010 | 896 | 0.230 |
Why?
|
Acute Disease | 7 | 2017 | 7241 | 0.220 |
Why?
|
Preoperative Period | 2 | 2019 | 564 | 0.220 |
Why?
|
Retrospective Studies | 19 | 2023 | 81635 | 0.220 |
Why?
|
Fluoroquinolones | 2 | 2015 | 307 | 0.210 |
Why?
|
Postoperative Complications | 5 | 2020 | 15831 | 0.210 |
Why?
|
Hypersensitivity | 2 | 2023 | 1169 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3110 | 0.200 |
Why?
|
Piperidines | 1 | 2011 | 1663 | 0.200 |
Why?
|
Massachusetts | 3 | 2021 | 8891 | 0.200 |
Why?
|
Biological Products | 1 | 2012 | 948 | 0.200 |
Why?
|
Lactams | 1 | 2022 | 159 | 0.190 |
Why?
|
Vagina | 2 | 2006 | 849 | 0.190 |
Why?
|
Hospitals | 5 | 2022 | 3888 | 0.190 |
Why?
|
Aged, 80 and over | 16 | 2021 | 59550 | 0.180 |
Why?
|
Leucine | 1 | 2022 | 547 | 0.180 |
Why?
|
Adult | 24 | 2023 | 223307 | 0.180 |
Why?
|
Blood Component Transfusion | 1 | 2021 | 141 | 0.180 |
Why?
|
Proline | 1 | 2022 | 454 | 0.180 |
Why?
|
Ritonavir | 1 | 2022 | 331 | 0.180 |
Why?
|
Drug Prescriptions | 2 | 2020 | 1663 | 0.170 |
Why?
|
Nursing Homes | 4 | 2023 | 1084 | 0.170 |
Why?
|
Multivariate Analysis | 4 | 2014 | 12064 | 0.170 |
Why?
|
Long-Term Care | 2 | 2021 | 630 | 0.160 |
Why?
|
Health Facility Environment | 1 | 2019 | 32 | 0.160 |
Why?
|
Cefazolin | 1 | 2019 | 94 | 0.160 |
Why?
|
Immunization, Passive | 1 | 2021 | 618 | 0.160 |
Why?
|
Enterobacteriaceae Infections | 2 | 2013 | 190 | 0.160 |
Why?
|
Patient Identification Systems | 1 | 2019 | 75 | 0.160 |
Why?
|
Documentation | 2 | 2016 | 914 | 0.160 |
Why?
|
Defibrillators, Implantable | 2 | 2020 | 1499 | 0.150 |
Why?
|
Skin | 1 | 2012 | 4499 | 0.150 |
Why?
|
Bacteriological Techniques | 1 | 2019 | 277 | 0.150 |
Why?
|
Plasma | 1 | 2021 | 583 | 0.150 |
Why?
|
Device Removal | 2 | 2021 | 643 | 0.150 |
Why?
|
Hernia, Inguinal | 1 | 2020 | 224 | 0.150 |
Why?
|
Hospitalization | 5 | 2021 | 10823 | 0.140 |
Why?
|
Predictive Value of Tests | 4 | 2016 | 15416 | 0.140 |
Why?
|
Personnel, Hospital | 1 | 2019 | 285 | 0.140 |
Why?
|
Cohort Studies | 8 | 2024 | 41710 | 0.140 |
Why?
|
Arthroplasty | 1 | 2019 | 308 | 0.140 |
Why?
|
Nitriles | 1 | 2022 | 981 | 0.140 |
Why?
|
Time Factors | 8 | 2024 | 40149 | 0.140 |
Why?
|
Confidence Intervals | 2 | 2014 | 2921 | 0.140 |
Why?
|
Protective Clothing | 1 | 2017 | 103 | 0.140 |
Why?
|
Skilled Nursing Facilities | 1 | 2021 | 406 | 0.130 |
Why?
|
Propensity Score | 1 | 2024 | 1972 | 0.130 |
Why?
|
Pneumonia | 2 | 2020 | 2159 | 0.130 |
Why?
|
Klebsiella | 1 | 2015 | 49 | 0.130 |
Why?
|
Specimen Handling | 1 | 2020 | 706 | 0.120 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2011 | 3636 | 0.120 |
Why?
|
Drug Combinations | 2 | 2022 | 2085 | 0.120 |
Why?
|
Laboratories, Hospital | 1 | 2017 | 192 | 0.120 |
Why?
|
Hand | 2 | 2011 | 909 | 0.120 |
Why?
|
Empirical Research | 1 | 2015 | 119 | 0.120 |
Why?
|
Probability | 1 | 2020 | 2476 | 0.120 |
Why?
|
Patient Education as Topic | 2 | 2017 | 2334 | 0.120 |
Why?
|
Animal Husbandry | 1 | 2015 | 64 | 0.120 |
Why?
|
Gentamicins | 1 | 2015 | 244 | 0.120 |
Why?
|
Referral and Consultation | 2 | 2017 | 3618 | 0.120 |
Why?
|
Epithelial Cells | 1 | 2006 | 3691 | 0.120 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 6307 | 0.120 |
Why?
|
Ceftriaxone | 1 | 2015 | 176 | 0.120 |
Why?
|
Remote Consultation | 1 | 2017 | 241 | 0.120 |
Why?
|
Prevalence | 6 | 2019 | 15835 | 0.110 |
Why?
|
Electronics, Medical | 1 | 2014 | 70 | 0.110 |
Why?
|
Research | 2 | 2019 | 1977 | 0.110 |
Why?
|
Patient Isolation | 1 | 2014 | 101 | 0.110 |
Why?
|
Cell Differentiation | 1 | 2011 | 11651 | 0.110 |
Why?
|
Pilot Projects | 2 | 2017 | 8728 | 0.100 |
Why?
|
Treatment Outcome | 10 | 2023 | 65273 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1394 | 0.100 |
Why?
|
Gram-Negative Bacteria | 1 | 2014 | 276 | 0.100 |
Why?
|
Leukocidins | 1 | 2012 | 18 | 0.100 |
Why?
|
Catheters, Indwelling | 1 | 2015 | 436 | 0.100 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 7871 | 0.100 |
Why?
|
Sentinel Surveillance | 1 | 2014 | 292 | 0.100 |
Why?
|
New England | 2 | 2013 | 1059 | 0.100 |
Why?
|
Colony Count, Microbial | 1 | 2013 | 326 | 0.100 |
Why?
|
Guideline Adherence | 2 | 2019 | 2234 | 0.100 |
Why?
|
Exotoxins | 1 | 2012 | 123 | 0.100 |
Why?
|
Nasopharyngeal Diseases | 1 | 2011 | 27 | 0.100 |
Why?
|
Intensive Care Units | 3 | 2017 | 3799 | 0.100 |
Why?
|
Feces | 1 | 2018 | 1505 | 0.100 |
Why?
|
Heterocyclic Compounds, Bridged-Ring | 1 | 2011 | 1 | 0.100 |
Why?
|
Meat | 1 | 2015 | 588 | 0.100 |
Why?
|
Interpersonal Relations | 1 | 2019 | 1432 | 0.100 |
Why?
|
Ambulatory Care Facilities | 1 | 2018 | 939 | 0.100 |
Why?
|
Automation | 1 | 2014 | 586 | 0.090 |
Why?
|
Penicillin-Binding Proteins | 1 | 2012 | 152 | 0.090 |
Why?
|
Treatment Failure | 1 | 2017 | 2659 | 0.090 |
Why?
|
Hospitals, Public | 1 | 2012 | 204 | 0.090 |
Why?
|
Quality Control | 1 | 2014 | 834 | 0.090 |
Why?
|
HL-60 Cells | 1 | 2011 | 365 | 0.090 |
Why?
|
Program Development | 1 | 2017 | 1297 | 0.090 |
Why?
|
Aerosols | 2 | 2024 | 634 | 0.090 |
Why?
|
Odds Ratio | 2 | 2014 | 9661 | 0.090 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 376 | 0.090 |
Why?
|
Molecular Epidemiology | 1 | 2012 | 473 | 0.090 |
Why?
|
Survival Analysis | 2 | 2021 | 10100 | 0.090 |
Why?
|
Poisson Distribution | 1 | 2011 | 507 | 0.090 |
Why?
|
Outpatients | 2 | 2016 | 1596 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2022 | 3070 | 0.080 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 12985 | 0.080 |
Why?
|
Receptors, GABA | 1 | 2011 | 312 | 0.080 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12534 | 0.080 |
Why?
|
Information Storage and Retrieval | 1 | 2015 | 832 | 0.080 |
Why?
|
Oropharynx | 1 | 2010 | 139 | 0.080 |
Why?
|
Travel | 1 | 2015 | 806 | 0.080 |
Why?
|
Communicable Diseases | 1 | 2017 | 872 | 0.080 |
Why?
|
Candidiasis | 1 | 2011 | 372 | 0.080 |
Why?
|
Catheters | 1 | 2011 | 428 | 0.080 |
Why?
|
Young Adult | 5 | 2021 | 59939 | 0.070 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14652 | 0.070 |
Why?
|
Wounds and Injuries | 2 | 2011 | 2513 | 0.070 |
Why?
|
Risk Adjustment | 1 | 2011 | 597 | 0.070 |
Why?
|
Placebos | 1 | 2012 | 1659 | 0.070 |
Why?
|
Prostate | 1 | 2015 | 1757 | 0.070 |
Why?
|
Adolescent | 7 | 2017 | 88904 | 0.070 |
Why?
|
Bacterial Toxins | 1 | 2012 | 922 | 0.070 |
Why?
|
Quality Improvement | 4 | 2018 | 3850 | 0.070 |
Why?
|
Bacteria | 2 | 2011 | 2212 | 0.070 |
Why?
|
Enterobacteriaceae | 1 | 2007 | 161 | 0.070 |
Why?
|
Urine | 1 | 2007 | 363 | 0.070 |
Why?
|
Statistics as Topic | 1 | 2012 | 2351 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2011 | 830 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3692 | 0.060 |
Why?
|
Drug Utilization | 1 | 2011 | 1187 | 0.060 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2005 | 32 | 0.060 |
Why?
|
Proton Pump Inhibitors | 1 | 2010 | 550 | 0.060 |
Why?
|
Mice, Nude | 1 | 2011 | 3616 | 0.060 |
Why?
|
Prospective Studies | 4 | 2018 | 54871 | 0.060 |
Why?
|
Databases, Factual | 2 | 2019 | 8066 | 0.060 |
Why?
|
Administration, Oral | 1 | 2012 | 4018 | 0.060 |
Why?
|
Neutropenia | 2 | 2019 | 894 | 0.060 |
Why?
|
Biopsy | 1 | 2015 | 6779 | 0.050 |
Why?
|
Air Microbiology | 1 | 2024 | 94 | 0.050 |
Why?
|
Trimethoprim Resistance | 1 | 2003 | 4 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2011 | 3607 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2017 | 4306 | 0.050 |
Why?
|
Patient Admission | 1 | 2010 | 1364 | 0.050 |
Why?
|
Patient Discharge | 1 | 2015 | 3465 | 0.050 |
Why?
|
Women's Health | 1 | 2012 | 2081 | 0.050 |
Why?
|
Staphylococcus | 1 | 2002 | 145 | 0.050 |
Why?
|
Monocytes | 1 | 2011 | 2600 | 0.050 |
Why?
|
Mortality | 1 | 2013 | 2910 | 0.050 |
Why?
|
DNA Damage | 1 | 2011 | 2467 | 0.050 |
Why?
|
Patient Readmission | 1 | 2015 | 3283 | 0.050 |
Why?
|
Pharmacists | 1 | 2023 | 261 | 0.040 |
Why?
|
Genome, Viral | 1 | 2024 | 674 | 0.040 |
Why?
|
Penicillins | 1 | 2023 | 404 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 4853 | 0.040 |
Why?
|
Biomedical Research | 1 | 2015 | 3459 | 0.040 |
Why?
|
Bacterial Proteins | 1 | 2012 | 3833 | 0.040 |
Why?
|
Protective Devices | 1 | 2019 | 72 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2017 | 5887 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2014 | 22248 | 0.040 |
Why?
|
Delphi Technique | 1 | 2022 | 892 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2012 | 5795 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2015 | 20144 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 2019 | 1622 | 0.030 |
Why?
|
Uropathogenic Escherichia coli | 1 | 2016 | 6 | 0.030 |
Why?
|
Electrophysiology | 1 | 2019 | 1263 | 0.030 |
Why?
|
Critical Pathways | 1 | 2020 | 475 | 0.030 |
Why?
|
Logistic Models | 1 | 2011 | 13278 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2012 | 14762 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2011 | 10445 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2354 | 0.030 |
Why?
|
Diarrhea | 1 | 2022 | 1317 | 0.030 |
Why?
|
Software Design | 1 | 2015 | 173 | 0.030 |
Why?
|
Health Priorities | 1 | 2018 | 380 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 17088 | 0.030 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2017 | 249 | 0.030 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2017 | 511 | 0.030 |
Why?
|
RNA, Viral | 1 | 2022 | 2867 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26310 | 0.030 |
Why?
|
Focus Groups | 1 | 2019 | 1459 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2018 | 811 | 0.030 |
Why?
|
Workplace | 1 | 2019 | 873 | 0.030 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2014 | 239 | 0.030 |
Why?
|
Interprofessional Relations | 1 | 2018 | 998 | 0.020 |
Why?
|
Comorbidity | 2 | 2017 | 10580 | 0.020 |
Why?
|
Data Mining | 1 | 2016 | 560 | 0.020 |
Why?
|
Home Care Services | 1 | 2018 | 659 | 0.020 |
Why?
|
Animals | 2 | 2015 | 168930 | 0.020 |
Why?
|
Child | 3 | 2019 | 80668 | 0.020 |
Why?
|
Anti-Infective Agents, Local | 1 | 2011 | 246 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1276 | 0.020 |
Why?
|
Fever | 1 | 2016 | 1607 | 0.020 |
Why?
|
Signal Transduction | 1 | 2011 | 23619 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2007 | 26389 | 0.020 |
Why?
|
Pregnancy | 2 | 2019 | 30237 | 0.020 |
Why?
|
Infant | 1 | 2007 | 36461 | 0.020 |
Why?
|
Spermatocidal Agents | 1 | 2005 | 15 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3927 | 0.020 |
Why?
|
Risk Assessment | 2 | 2020 | 24295 | 0.010 |
Why?
|
Child, Preschool | 1 | 2007 | 42577 | 0.010 |
Why?
|
Mice | 1 | 2011 | 81889 | 0.010 |
Why?
|
Inpatients | 1 | 2016 | 2565 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8735 | 0.010 |
Why?
|
Urinary Incontinence, Stress | 1 | 2005 | 180 | 0.010 |
Why?
|
Length of Stay | 1 | 2015 | 6490 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2005 | 1587 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39309 | 0.010 |
Why?
|
Risk | 1 | 2010 | 9602 | 0.010 |
Why?
|
Diabetes Complications | 1 | 2005 | 1319 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15908 | 0.010 |
Why?
|
Medicare | 1 | 2015 | 6820 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2005 | 2192 | 0.010 |
Why?
|